Ceretas Limited Lists on ASX, Secures $8 Million to Advance Alzheimer's Therapeutic Ultrasound Technology

Ceretas Debuts on ASX with Focus on Therapeutic Ultrasound for Neurodegenerative Diseases

Ceretas Limited officially began trading on the Australian Securities Exchange on 23 July 2026, marking a key milestone for the emerging medical technology company. Following its admission to the Official List on 21 July 2026, the company’s ordinary shares commenced quotation at 12:00pm AEST. This listing opens access to public capital markets for Ceretas, which is dedicated to developing innovative treatments for neurodegenerative diseases.

The company’s primary innovation is a portable, non-invasive therapeutic ultrasound platform designed to treat Alzheimer's disease and other neurodegenerative conditions. This technology positions Ceretas within the medical technology sector, addressing a significant clinical and commercial opportunity. The July 2026 listing aligns with favourable market conditions and the company’s readiness to secure public funding to advance its development and commercialisation plans.

$8 Million Capital Raise Through Fully-Paid Ordinary Shares

Ceretas successfully raised $8 million by issuing 32 million fully-paid ordinary shares at $0.25 each. This capital raising was conducted under a second replacement prospectus dated 7 July 2026, providing investors with detailed disclosures on the company’s business, financial status, and associated risks. The $0.25 per share price set the foundation for the company’s ASX listing valuation.

Post capital raise and ASX admission, 48,418,820 fully-paid ordinary shares are now quoted on the ASX under the code CTS. Automic Pty Ltd manages the share registry from Level 5, 126 Phillip Street, Sydney NSW 2000. Shareholders can contact the registry on 1300 288 664 within Australia or +61 2 9698 5414 internationally during business hours. The successful capital raise highlights strong investor interest in medical technology firms targeting critical neurological conditions.

Escrow Restrictions on Significant Share Holdings

The ASX has imposed standard restricted securities classifications on Ceretas’s share capital following listing. Specifically, 20,494,680 fully-paid ordinary shares are restricted and subject to escrow until 23 July 2028, representing a 24-month lock-up from quotation date. Additionally, 2,461,500 fully-paid ordinary shares are escrowed until 5 January 2027, reflecting a 12-month period from issue under the prospectus.

Options and performance rights are also escrowed: 4 million options exercisable at $0.375 until 21 July 2029 and 3.6 million options exercisable at $0.375 until 15 July 2031 are escrowed until 23 July 2028. Furthermore, 2 million performance rights remain restricted until 23 July 2028. These escrow arrangements promote management and shareholder alignment and contribute to market stability during Ceretas’s early public phase.

Unquoted Securities Enhance Capital Structure Flexibility

Ceretas holds additional unquoted securities including 150,000 options exercisable at $0.375 until 15 July 2029 and 1,830,000 options exercisable at $0.375 until 15 July 2031. There are also 500,000 unquoted performance rights. These instruments serve as equity incentives and support capital structure flexibility, aligning employee interests with company performance.

Capital Raise Led by Caravel Securities and Taurus Capital

Caravel Securities and Taurus Capital acted as joint lead managers for the $8 million capital raise and ASX listing. They coordinated the issuance and distribution of 32 million new shares at $0.25 each. Notably, no underwriter was appointed, indicating the offering was managed without a firm underwriting commitment. This approach is common for newly listed companies with strong investor demand. The successful raise without underwriting underscores robust investor confidence in Ceretas’s technology and management.

Corporate Governance and Registered Office Information

Ceretas Limited is registered in Australia, with its registered office at Level 4, 260 Queen Street, Brisbane QLD 4000. Contact details include telephone 07 3543 4424 and email [email protected]. Nicki Farley serves as company secretary, overseeing governance and administration. These details are publicly accessible for shareholders and stakeholders.

As a CHESS Participating entity, Ceretas operates within the ASX’s electronic settlement system, offering both CHESS and Issuer Sponsored shareholding options. The company’s International Securities Identification Number (ISIN) for fully-paid ordinary shares is AU0000475766, facilitating international securities settlement.

Focus on Neurodegenerative Disease Therapeutic Innovation

Ceretas’s core business is the development of a portable, non-invasive therapeutic ultrasound platform aimed at treating Alzheimer's and other neurodegenerative diseases. This innovative technology addresses significant unmet clinical needs and represents a promising commercial opportunity. The platform’s portability and non-invasive nature may provide enhanced patient safety and accessibility compared to existing treatments.

Targeting Alzheimer’s and related conditions situates Ceretas within a growing market driven by increasing prevalence and ageing populations. The therapeutic ultrasound approach offers a novel alternative to traditional pharmaceuticals. Funds raised through the IPO will support continued development, clinical validation, and preparation for regulatory approvals and commercialisation across multiple jurisdictions.

Dividend Policy and Financial Reporting

Ceretas’s dividend policy is outlined in section 4.10 of the second replacement prospectus dated 7 July 2026. Investors seeking details on dividend distribution, frequency, and influencing factors should consult this primary disclosure document.

The company’s financial year ends on 30 June, with half-year reporting at 31 December, aligning with standard Australian financial reporting practices for ASX-listed entities. This facilitates transparent financial disclosure and comparability with peers in the medical technology and healthcare sectors.

Share Registry and Shareholder Services

Automic Pty Ltd manages Ceretas’s share registry, handling shareholder records, dividend distributions, and administrative services. The registry is located at Level 5, 126 Phillip Street, Sydney NSW 2000. Shareholders can contact Automic on 1300 288 664 (Australia) or +61 2 9698 5414 (international) Monday to Friday, 6:30am to 5:00pm AWST, excluding public holidays. Registry inquiries such as share transfers, address updates, and dividend questions should be directed to Automic rather than the company’s registered office.

Engagement of a professional share registry ensures efficient administration and supports both domestic and international shareholders, reflecting Ceretas’s global investor interest in its medical technology platform.

Market Outlook and Development Prospects

Ceretas’s ASX listing in July 2026 reflects favourable market conditions and investor enthusiasm for innovative medical technology ventures. The $8 million capital raise completed without underwriting highlights strong confidence in the company’s technology and leadership. However, immediate post-listing share price performance was not disclosed at the time.

Looking ahead, investors will monitor Ceretas’s progress on key milestones including therapeutic ultrasound platform development, clinical validation, and regulatory approvals. Escrow restrictions until 23 July 2028 indicate a medium-term commitment from major shareholders and early investors. The company’s success will depend on achieving clinical and regulatory milestones and demonstrating commercial viability through market adoption for Alzheimer’s and neurodegenerative disease treatments.